CLINICAL AND ECONOMIC IMPACT OF AN OPTIMIZED MESALAZINE-BASED MANAGEMENT STRATEGY VERSUS CURRENT STANDARD CARE IN PATIENTS WITH MILD-TO-MODERATE LEFT-SIDED ULCERATIVE COLITIS IN THE NETHERLANDS: A COST-OFFSET ANALYSIS
Author(s)
Margarita Landeira, Master of Science1, Iwona Zerda, MSc2, Barry Rodgers-Gray, MD3, Bolette Christophersen, MD4, Marleen Roelfsema, Master of Science5.
1Associate Director HEOR, Ferring Pharmaceuticals, Madrid, Spain, 2Clever-Access, Krakow, Poland, 3Ferring Pharmaceuticals, West Drayton, United Kingdom, 4Ferring Pharmaceuticals, Copenhagen, Denmark, 5Ferring Pharmaceuticals, Hoofddorp, Netherlands.
1Associate Director HEOR, Ferring Pharmaceuticals, Madrid, Spain, 2Clever-Access, Krakow, Poland, 3Ferring Pharmaceuticals, West Drayton, United Kingdom, 4Ferring Pharmaceuticals, Copenhagen, Denmark, 5Ferring Pharmaceuticals, Hoofddorp, Netherlands.
OBJECTIVES: Ulcerative colitis (UC) is associated with recurrent disease flares, healthcare resource utilization, and substantial long-term costs. This cost-offset model evaluated an optimized mesalazine-based strategy versus standard care (SoC) in patients with M2M left-sided UC in the Netherlands.
METHODS: A Markov cohort model simulated 100 patients with M2M left-sided UC from a Dutch healthcare payer perspective. The optimized strategy reflected a proactive mesalazine-based approach aimed at maintaining disease control and delaying escalation to advanced therapies, whereas SoC reflected current Dutch practice with earlier treatment escalation following relapses. Clinical inputs and costs were based on published literature and Dutch practice. Outcomes included disease flares, hospitalizations, adverse events (AEs), treatment utilization, colectomy rates, and healthcare costs. Litetime (3% discount rate) and 10- and 20- year horizons scenario analyses (SA) were conducted.
RESULTS: Over a lifetime horizon, the optimized strategy reduced disease flares by 126.7 events (4.6%; 2,644.7 vs. 2,771.4), hospitalizations by 5.5 events (5.5%; 93.5 vs. 99.0), advanced therapy utilization by 1.5% (95.9% vs. 97.4%), colectomy rates by 4.8% (30.4% vs. 31.9%), and AEs by 17.4% (3.86 vs. 4.67 events) versus SoC. Healthcare costs decreased from €24.79 million to €24.20 million, generating savings of €590,755 per 100 patients. The 10-year SA showed cost savings of €390,453 and 20-year SA €648,471. At 10 years, reductions in flares, hospitalizations, advanced therapy utilization, colectomy rates, and AEs were 10.6%, 17.4%, 16.3%, 17.3%, and 20.3%, respectively; corresponding reductions at 20 years were 8.5%, 11.6%, 6.8%, 10.4%, and 17.8%.
CONCLUSIONS: An optimized mesalazine-based management strategy improved clinical outcomes and reduced healthcare costs versus SoC in patients with M2M left-sided UC in the Netherlands. Benefits were greatest over 10- and 20-year horizons. Smaller lifetime differences reflected eventual progression to advanced therapies in both strategies. Mesalazine treatment optimization may improve disease control, delay treatment escalation, and reduce healthcare costs.
METHODS: A Markov cohort model simulated 100 patients with M2M left-sided UC from a Dutch healthcare payer perspective. The optimized strategy reflected a proactive mesalazine-based approach aimed at maintaining disease control and delaying escalation to advanced therapies, whereas SoC reflected current Dutch practice with earlier treatment escalation following relapses. Clinical inputs and costs were based on published literature and Dutch practice. Outcomes included disease flares, hospitalizations, adverse events (AEs), treatment utilization, colectomy rates, and healthcare costs. Litetime (3% discount rate) and 10- and 20- year horizons scenario analyses (SA) were conducted.
RESULTS: Over a lifetime horizon, the optimized strategy reduced disease flares by 126.7 events (4.6%; 2,644.7 vs. 2,771.4), hospitalizations by 5.5 events (5.5%; 93.5 vs. 99.0), advanced therapy utilization by 1.5% (95.9% vs. 97.4%), colectomy rates by 4.8% (30.4% vs. 31.9%), and AEs by 17.4% (3.86 vs. 4.67 events) versus SoC. Healthcare costs decreased from €24.79 million to €24.20 million, generating savings of €590,755 per 100 patients. The 10-year SA showed cost savings of €390,453 and 20-year SA €648,471. At 10 years, reductions in flares, hospitalizations, advanced therapy utilization, colectomy rates, and AEs were 10.6%, 17.4%, 16.3%, 17.3%, and 20.3%, respectively; corresponding reductions at 20 years were 8.5%, 11.6%, 6.8%, 10.4%, and 17.8%.
CONCLUSIONS: An optimized mesalazine-based management strategy improved clinical outcomes and reduced healthcare costs versus SoC in patients with M2M left-sided UC in the Netherlands. Benefits were greatest over 10- and 20-year horizons. Smaller lifetime differences reflected eventual progression to advanced therapies in both strategies. Mesalazine treatment optimization may improve disease control, delay treatment escalation, and reduce healthcare costs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE641
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Gastrointestinal Disorders